Top

Published in:

Open Access 01-12-2014 | Research

Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck

Authors: Mathias Gehrmann, Hanno M Specht, Christine Bayer, Markus Brandstetter, Barbara Chizzali, Marciana Duma, Stephanie Breuninger, Kathrin Hube, Sophie Lehnerer, Valerie van Phi, Eva Sage, Thomas E Schmid, Michael Sedelmayr, Daniela Schilling, Wolfgang Sievert, Stefan Stangl, Gabriele Multhoff

Published in: Radiation Oncology | Issue 1/2014

Abstract

Background

Tumor but not normal cells frequently overexpress heat shock protein 70 (Hsp70) and present it on their cell surface (mHsp70) from where it can be actively released. Therefore, membrane (mHsp70) and soluble Hsp70 (sHsp70) were investigated as potential tumor biomarkers and for monitoring the outcome of radiation therapy.

Methods

Biopsies and blood were collected from patients with squamous cell carcinoma of the head and neck (SCCHN) at different time points (before, during therapy and in the follow-up period). Hsp70 membrane expression was determined on single cell suspensions of tumor biopsies and reference tissues by flow cytometry, sHsp70 protein and antibody levels were determined in the serum of patients and healthy donors by ELISA and NK cell markers that are related to the presence of sHsp70 were analyzed in the patient’s peripheral blood lymphocytes (PBL).

Results

Tumor biopsies exhibited significantly increased mHsp70 expression levels compared to the reference tissue. Soluble Hsp70 levels were significantly higher in SCCHN patients compared to healthy human volunteers and high mHsp70 expression levels on tumor cells were associated with high sHsp70 levels in the serum of patients. Following surgery and radiotherapy sHsp70 levels in patients dropped in patients without tumor relapse in the follow-up period. In contrast to sHsp70 protein, anti-Hsp70 antibody levels remained nearly unaltered in the serum of SCCHN patients before and after therapy. Furthermore, sHsp70 protein but not anti-Hsp70 antibody levels were found to be associated with the tumor volume in SCCHN patients before start of therapy. The expression densities of the activatory NK cell markers CD56, CD94, NKG2D, NKp30, Nkp44, and NKp46 differed in patients following therapeutic intervention. A significant increase in the density of NKG2D was observed in SCCHN patients in the follow-up period after surgery and radiotherapy.

Conclusion

We suggest sHsp70 as a potential biomarker for detecting tumors and for monitoring the clinical outcome of radiotherapy in SCCHN patients.

Available only for authorised users

de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR: Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013, 46: 466-479. 10.1016/j.clinbiochem.2012.10.039CrossRefPubMed

Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer 2013, 13: 366. 10.1186/1471-2407-13-366PubMedCentralCrossRefPubMed

Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW: Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 2004, 3: 49-53. 10.3816/CGC.2004.n.013CrossRefPubMed

Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N: Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008, 263: 280-290. 10.1016/j.canlet.2008.01.013CrossRefPubMed

Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10: 86-103. 10.1379/CSC-99r.1PubMedCentralCrossRefPubMed

Calini V, Urani C, Camatini M: Overexpression of HSP70 is induced by ionizing radiation in C3H 10 T1/2 cells and protects from DNA damage. Toxicol In Vitro 2003, 17: 561-566. 10.1016/S0887-2333(03)00116-4CrossRefPubMed

Rerole AL, Jego G, Garrido C: Hsp70: anti-apoptotic and tumorigenic protein. Methods Mol Biol 2011, 787: 205-230. 10.1007/978-1-61779-295-3_16CrossRefPubMed

Multhoff G: Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. Methods 2007, 43: 229-237. 10.1016/j.ymeth.2007.06.006CrossRefPubMed

Lancaster GI, Febbraio MA: Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 2005, 280: 23349-23355. 10.1074/jbc.M502017200CrossRefPubMed

10.

Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000, 6: 435-442. 10.1038/74697CrossRefPubMed

11.

Gross C, Hansch D, Gastpar R, Multhoff G: Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem 2003, 384: 267-279.CrossRefPubMed

12.

Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G: The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 2004, 172: 972-980. 10.4049/jimmunol.172.2.972CrossRefPubMed

13.

Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G: Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models. Int J Radiat Oncol Biol Phys 2014, 88: 694-700. 10.1016/j.ijrobp.2013.11.008CrossRefPubMed

14.

Kleinjung T, Arndt O, Feldmann HJ, Bockmühl U, Gehrmann M, Zilch T, Pfister K, Schönberger J, Marienhagen J, Eilles C, Rossbacher L, Multhoff G: Heat shock protein 70 (Hsp70) membrane expression on head-and-neck cancer biopsy-a target for natural killer (NK) cells. Int J Radiat Oncol Biol Phys 2003, 57: 820-826. 10.1016/S0360-3016(03)00629-1CrossRefPubMed

15.

Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 2004, 10: 3699-3707. 10.1158/1078-0432.CCR-03-0683CrossRefPubMed

16.

Dutta SK, Girotra M, Singla M, Dutta A, Otis Stephen F, Nair PP, Merchant NB: Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas 2012, 41: 530-534. 10.1097/MPA.0b013e3182374acePubMedCentralCrossRefPubMed

17.

Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H: An investigation into the potential use of serum Hsp70 as a novel tumor biomarker for Hsp90 inhibitors. Biomarkers 2010, 15: 31-38. 10.3109/13547500903261347CrossRefPubMed

18.

Baumann M, Liertz C, Baisch H, Wiegel T, Lorenzen J, Arps H: Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiother Oncol 1994, 32: 137-143. 10.1016/0167-8140(94)90100-7CrossRefPubMed

19.

Hurwitz MD, Kaur P, Nagaraja GM, Bausero MA, Manola J, Asea A: Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother Oncol 2010, 95: 350-358. 10.1016/j.radonc.2010.03.024PubMedCentralCrossRefPubMed

20.

De Maio A: Heat shock proteins: facts, thoughts, and dreams. Shock 1999, 11: 1-12.CrossRefPubMed

21.

Gross C, Schmidt-Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart LA, Multhoff G: Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones 2003, 8: 348-360. 10.1379/1466-1268(2003)008<0348:HSPRIA>2.0.CO;2PubMedCentralCrossRefPubMed

22.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105: 10513-10518. 10.1073/pnas.0804549105PubMedCentralCrossRefPubMed

23.

Kocsis J, Madaras B, Toth EK, Fust G, Prohaszka Z: Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis. Cell Stress Chaperones 2010, 15: 143-151. 10.1007/s12192-009-0128-7PubMedCentralCrossRefPubMed

24.

Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, Rozsas A, Ostoros G, Laszlo V, Hofbauer H, Renyi-Vamos F, Klepetko W, Dome B, Ankersmit HJ: Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case–control study. Clin Chim Acta 2012, 413: 1115-1120. 10.1016/j.cca.2012.03.008CrossRefPubMed

Title: Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck
Authors: Mathias Gehrmann
Hanno M Specht
Christine Bayer
Markus Brandstetter
Barbara Chizzali
Marciana Duma
Stephanie Breuninger
Kathrin Hube
Sophie Lehnerer
Valerie van Phi
Eva Sage
Thomas E Schmid
Michael Sedelmayr
Daniela Schilling
Wolfgang Sievert
Stefan Stangl
Gabriele Multhoff
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-9-131

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk?

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

IMRT with 18FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer

Integrating microRNA and mRNA expression profiles in response to radiation-induced injury in rat lung

Can combined intracavitary/interstitial approach be an alternative to interstitial brachytherapy with the Martinez Universal Perineal Interstitial Template (MUPIT) in computed tomography-guided adaptive brachytherapy for bulky and/or irregularly shaped gynecological tumors?